Intranasal Immunization with CTL Epitope Peptides from HIV-1 or Ovalbumin and the Mucosal Adjuvant Cholera Toxin Induces Peptide-Specific CTLs and Protection Against Tumor Development in Vivo

Angel Porgador, Herman F. Staats, Brenda Faiola, Eli Gilboa, Thomas J. Palker

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

To evaluate the ability of mucosal immunization protocols using peptide immunogens to induce CTL responses, BALB/c and C57BL/6 mice were immunized intranasally (i.n.) with peptides corresponding to a known CTL epitope in HIV-1 glycoprotein 120 or OVA, respectively, and the mucosal adjuvant cholera toxin (CT). Intranasal immunization of BALB/c mice with a 10- or 15-amino acid peptide corresponding to a CTL determinant in HIV-1 glycoprotein 120 and CT induced peptide-specific CTLs in spleen cells that persisted through 35 days after the last immunization. Intranasal immunization of C57BL/6 mice with the octameric OVA peptide and CT produced similar results with detectable peptide-specific CTL in both the cervical lymph node and spleen. To test whether CTL induced by i.n. immunization with OVA peptide and CT were functional in vivo, groups of C57BL/6 mice were injected with E.G7-OVA tumor cells that express the OVA protein and monitored for tumor growth. Animals immunized i.n. with OVA and CT were protected against tumor development as efficiently as animals immunized by the potent CTL induction protocol of i.v. injection with OVA-pulsed dendritic cells. Intranasal immunization with peptides corresponding to known CTL epitopes and CT provides a noninvasive route of immunization for the induction of CTL responses in vivo.

Original languageEnglish
Pages (from-to)834-841
Number of pages8
JournalJournal of Immunology
Volume158
Issue number2
StatePublished - Jan 15 1997
Externally publishedYes

Fingerprint

Cholera Toxin
Ovalbumin
HIV-1
Epitopes
Immunization
Peptides
Neoplasms
Inbred C57BL Mouse
Glycoproteins
Spleen
Dendritic Cells
Lymph Nodes
Amino Acids
Injections
Growth

ASJC Scopus subject areas

  • Immunology

Cite this

Intranasal Immunization with CTL Epitope Peptides from HIV-1 or Ovalbumin and the Mucosal Adjuvant Cholera Toxin Induces Peptide-Specific CTLs and Protection Against Tumor Development in Vivo. / Porgador, Angel; Staats, Herman F.; Faiola, Brenda; Gilboa, Eli; Palker, Thomas J.

In: Journal of Immunology, Vol. 158, No. 2, 15.01.1997, p. 834-841.

Research output: Contribution to journalArticle

@article{03bc687519c54fd1a01f7fd51c3d0d54,
title = "Intranasal Immunization with CTL Epitope Peptides from HIV-1 or Ovalbumin and the Mucosal Adjuvant Cholera Toxin Induces Peptide-Specific CTLs and Protection Against Tumor Development in Vivo",
abstract = "To evaluate the ability of mucosal immunization protocols using peptide immunogens to induce CTL responses, BALB/c and C57BL/6 mice were immunized intranasally (i.n.) with peptides corresponding to a known CTL epitope in HIV-1 glycoprotein 120 or OVA, respectively, and the mucosal adjuvant cholera toxin (CT). Intranasal immunization of BALB/c mice with a 10- or 15-amino acid peptide corresponding to a CTL determinant in HIV-1 glycoprotein 120 and CT induced peptide-specific CTLs in spleen cells that persisted through 35 days after the last immunization. Intranasal immunization of C57BL/6 mice with the octameric OVA peptide and CT produced similar results with detectable peptide-specific CTL in both the cervical lymph node and spleen. To test whether CTL induced by i.n. immunization with OVA peptide and CT were functional in vivo, groups of C57BL/6 mice were injected with E.G7-OVA tumor cells that express the OVA protein and monitored for tumor growth. Animals immunized i.n. with OVA and CT were protected against tumor development as efficiently as animals immunized by the potent CTL induction protocol of i.v. injection with OVA-pulsed dendritic cells. Intranasal immunization with peptides corresponding to known CTL epitopes and CT provides a noninvasive route of immunization for the induction of CTL responses in vivo.",
author = "Angel Porgador and Staats, {Herman F.} and Brenda Faiola and Eli Gilboa and Palker, {Thomas J.}",
year = "1997",
month = "1",
day = "15",
language = "English",
volume = "158",
pages = "834--841",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Intranasal Immunization with CTL Epitope Peptides from HIV-1 or Ovalbumin and the Mucosal Adjuvant Cholera Toxin Induces Peptide-Specific CTLs and Protection Against Tumor Development in Vivo

AU - Porgador, Angel

AU - Staats, Herman F.

AU - Faiola, Brenda

AU - Gilboa, Eli

AU - Palker, Thomas J.

PY - 1997/1/15

Y1 - 1997/1/15

N2 - To evaluate the ability of mucosal immunization protocols using peptide immunogens to induce CTL responses, BALB/c and C57BL/6 mice were immunized intranasally (i.n.) with peptides corresponding to a known CTL epitope in HIV-1 glycoprotein 120 or OVA, respectively, and the mucosal adjuvant cholera toxin (CT). Intranasal immunization of BALB/c mice with a 10- or 15-amino acid peptide corresponding to a CTL determinant in HIV-1 glycoprotein 120 and CT induced peptide-specific CTLs in spleen cells that persisted through 35 days after the last immunization. Intranasal immunization of C57BL/6 mice with the octameric OVA peptide and CT produced similar results with detectable peptide-specific CTL in both the cervical lymph node and spleen. To test whether CTL induced by i.n. immunization with OVA peptide and CT were functional in vivo, groups of C57BL/6 mice were injected with E.G7-OVA tumor cells that express the OVA protein and monitored for tumor growth. Animals immunized i.n. with OVA and CT were protected against tumor development as efficiently as animals immunized by the potent CTL induction protocol of i.v. injection with OVA-pulsed dendritic cells. Intranasal immunization with peptides corresponding to known CTL epitopes and CT provides a noninvasive route of immunization for the induction of CTL responses in vivo.

AB - To evaluate the ability of mucosal immunization protocols using peptide immunogens to induce CTL responses, BALB/c and C57BL/6 mice were immunized intranasally (i.n.) with peptides corresponding to a known CTL epitope in HIV-1 glycoprotein 120 or OVA, respectively, and the mucosal adjuvant cholera toxin (CT). Intranasal immunization of BALB/c mice with a 10- or 15-amino acid peptide corresponding to a CTL determinant in HIV-1 glycoprotein 120 and CT induced peptide-specific CTLs in spleen cells that persisted through 35 days after the last immunization. Intranasal immunization of C57BL/6 mice with the octameric OVA peptide and CT produced similar results with detectable peptide-specific CTL in both the cervical lymph node and spleen. To test whether CTL induced by i.n. immunization with OVA peptide and CT were functional in vivo, groups of C57BL/6 mice were injected with E.G7-OVA tumor cells that express the OVA protein and monitored for tumor growth. Animals immunized i.n. with OVA and CT were protected against tumor development as efficiently as animals immunized by the potent CTL induction protocol of i.v. injection with OVA-pulsed dendritic cells. Intranasal immunization with peptides corresponding to known CTL epitopes and CT provides a noninvasive route of immunization for the induction of CTL responses in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0031567923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031567923&partnerID=8YFLogxK

M3 - Article

C2 - 8993001

AN - SCOPUS:0031567923

VL - 158

SP - 834

EP - 841

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -